Clinical significance of elevated lipoprotein(a) in primary and secondary prevention: a multi-institutional study
Lp(a) levels ≥30 mg/dL independently predicted adverse cardiovascular outcomes, regardless of baseline ASCVD status. This threshold appears suitable for cardiovascular risk stratification in both primary and secondary prevention settings.
Authors
- Pao‐Hsien Chu (ORCID: https://orcid.org/0000-0003-0361-6348)
- Tien‐Hsing Chen (ORCID: https://orcid.org/0000-0001-6986-9765)
- Kuo‐Chun Hung (ORCID: https://orcid.org/0000-0001-8655-3711)
- Dong‐Yi Chen (ORCID: https://orcid.org/0000-0002-9544-5496)
- Chieh-Yu Chang (ORCID: https://orcid.org/0000-0002-9288-0943)
- Ching‐Lin Hsieh (ORCID: https://orcid.org/0000-0001-9468-9969)
- Ming‐Jer Hsieh (ORCID: https://orcid.org/0000-0002-0148-8357)
- Ming‐Lung Tsai (ORCID: https://orcid.org/0000-0002-4199-713X)
- Shao‐Wei Chen (ORCID: https://orcid.org/0000-0003-1674-1295)
- Chun-Chi Chen (ORCID: https://orcid.org/0009-0009-4728-5393)
- Ming-Shien Wen
Institutions
- Chang Gung University (TW)
- National Tsing Hua University (TW)
- Chang Gung Memorial Hospital (TW)
- Taipei Municipal YangMing Hospital (TW)
- Keelung Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1093/eurjpc/zwaf649
- Citations
- 5
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 10.03